POSTOPERATIVE PACLITAXEL FOLLOWED BY PACLITAXEL AND CISPLATIN IN HEAD/NECK CA

头颈部 CA 术后使用紫杉醇，随后使用紫杉醇和顺铂

• 批准号: 7376264
• 负责人: ELLEN L ZAKRIS
• 金额: $ 0.06万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376264
• 关键词: POSTOPERATIVE; PACLITAXEL; FOLLOWED; CISPLATIN; HEAD

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients will receive chemotherapy using the drug Paclitaxel (Taxol) once a week for 3 weeks. The first dose is scheduled to be given about 2 weeks after surgery. Paclitaxel will be injected into a vein in the arm and will take about one hour to administer. This procedure will be given on an outpatient basis unless they are still in the hospital. After completion of the above treatment (approximately 5 weeks after surgery), they will receive radiation treatments once a day, 5 days a week for 5 1/2 to 7 weeks depending on the cancer. Treatments will be aimed at the prior location of the tumor on the head and neck. All radiation treatments will be given as an outpatient. Starting the third week of radiotherapy, they will receive the chemotherapy drugs Paclitaxel and Cisplatin, once a week until the end of radiation. These will be injected into a vein in the arm over a period of 4-5 hours. The chemotherapy treatments will be given on an outpatient basis. During the study, patients will have weekly physical exams, medical histories, blood tests (approximately 2 tablespoons) to assess cell counts and kidney/liver function, and any or all of the following (based on status of patient): chest x-ray, CT/MRI scan of the neck, CT scan of chest and/or abdomen, bone scan, dental evaluation or nutritional evaluation may be performed if necessary to check for side effects or the cancer. Follow-up for patients on this study involves: exam and biopsy under anesthesia to confirm recurrence, complete head and neck clinical exams by the head and neck surgeon and/or radiation oncologist every 3 months from end of treatment for 2 years, then every 6 months for 3 years, then anually. Patients should have a "baseline" CT or MRI at 8-10 weeks after completion of all therapy and then only as clinically indicated, chest x-ray every 6 months and blood tests and other scans or x-rays as deemed clinically indicated. Patients are followed for life regarding several status on an annual basis.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。患者将接受化疗，使用药物紫杉醇（紫杉醇）每周一次，持续3周。第一次剂量计划在手术后约2周给予。紫杉醇将被注射到手臂的静脉中，大约需要一个小时的时间。除非患者仍在医院，否则将在门诊进行此手术。在完成上述治疗后（手术后约5周），他们将接受放射治疗，每天一次，每周5天，持续5 1/2至7周，具体取决于癌症。治疗将针对肿瘤在头部和颈部的先前位置。所有放射治疗将作为门诊进行。从放疗的第三周开始，他们将接受化疗药物Paclitazone和顺铂，每周一次，直到放疗结束。这些将在4-5小时内注射到手臂的静脉中。化疗治疗将在门诊进行。在研究期间，患者将每周进行身体检查，病史，血液检查（约2汤匙），以评估细胞计数和肾/肝功能，以及以下任何或所有（基于患者的状态）：胸部X光、颈部CT/MRI扫描、胸部和/或腹部CT扫描、骨扫描，如有必要，可进行牙科评估或营养评估，以检查副作用或癌症。本研究患者的随访包括：麻醉下检查和活检以确认复发，头颈外科医生和/或放射肿瘤学家从治疗结束后每3个月进行一次完整的头颈部临床检查，持续2年，然后每6个月进行一次，持续3年，然后每年一次。患者应在完成所有治疗后8-10周进行“基线”CT或MRI，然后仅根据临床指征进行，每6个月进行一次胸部X光检查，并根据临床指征进行血液检查和其他扫描或X光检查。每年对患者进行几种状态的终身随访。